Lifecore Biomedical, Inc.
LFCRNASDAQHealthcare● Active
$5.55
$-0.08(-1.42%)
Market Cap$208177209
P/E Ratio—
52W High$8.98
52W Low$3.63
Lifecore Biomedical, Inc. (LFCR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LFCR · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
-$0.43
Est. -$0.29 · -48.3%
Revenue
$0.02B
Est. $0.03B · -10.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
LFCR reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$0.29 | — | — | — | $0.03B | — |
| ◌ Q3 FY2026 | Jul 31, 2026 | -$0.24 | — | — | — | $0.03B | — |
| ▼ Q2 FY2026 | May 6, 2026 | -$0.29 | -$0.43 | -48.3% | $0.02B | $0.03B | -10.7% |
| ▼ Q2 FY2026 | May 6, 2026 | -$0.24 | -$0.43 | -79.2% | — | $0.03B | — |
| ▲ Q1 FY2026 | Mar 16, 2026 | -$0.27 | -$0.16 | +40.7% | $0.04B | $0.03B | +6.1% |
| ◌ Q1 FY2026 | Jan 1, 2026 | -$0.29 | — | — | — | $0.03B | — |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.30 | -$0.29 | +3.3% | $0.03B | $0.03B | +17.5% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.09 | -$0.10 | -11.1% | $0.04B | $0.03B | +44.3% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$0.29
EPS Surpr.
—
Revenue
—
Q3 FY2026
Jul 31, 2026
EPS Actual
—
EPS Est.
-$0.24
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Miss
EPS Actual
-$0.43
EPS Est.
-$0.29
EPS Surpr.
-48.3%
Revenue
$0.02B
Q2 FY2026
May 6, 2026Miss
EPS Actual
-$0.43
EPS Est.
-$0.24
EPS Surpr.
-79.2%
Revenue
—
Q1 FY2026
Mar 16, 2026Beat
EPS Actual
-$0.16
EPS Est.
-$0.27
EPS Surpr.
+40.7%
Revenue
$0.04B
Q1 FY2026
Jan 1, 2026
EPS Actual
—
EPS Est.
-$0.29
EPS Surpr.
—
Revenue
—
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.29
EPS Est.
-$0.30
EPS Surpr.
+3.3%
Revenue
$0.03B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.10
EPS Est.
-$0.09
EPS Surpr.
-11.1%
Revenue
$0.04B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2033 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2033 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2032 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2032 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2032 | $-0.18 | $-0.17 | $-0.15 | 1 |
| Q1 FY2032 | $-0.22 | $-0.20 | $-0.19 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2033 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2033 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2032 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2032 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2032 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2032 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 6, 2026 | -48.3% | $5.16 | $4.96 | -3.88% |
| ▼ Q2 FY2026 | May 6, 2026 | -79.2% | $5.16 | $4.96 | -3.88% |
| ▲ Q1 FY2026 | Mar 16, 2026 | +40.7% | $6.54 | $4.37 | -33.18% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +3.3% | $6.77 | $6.62 | -2.22% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -11.1% | $7.73 | $7.76 | +0.39% |
| ▼ Q2 FY2025 | Apr 3, 2025 | -35.7% | $7.20 | $6.81 | -5.42% |
| ▲ Q1 FY2025 | Jan 2, 2025 | +7.4% | $7.43 | $6.66 | -10.36% |
| ▼ Q4 FY2024 | Oct 4, 2024 | -6.5% | $4.71 | $5.38 | +14.23% |
Q2 FY2026-3.88%
Report Date
May 6, 2026
EPS Beat/Miss
-48.3%
Price Before
$5.16
Price After
$4.96
Q2 FY2026-3.88%
Report Date
May 6, 2026
EPS Beat/Miss
-79.2%
Price Before
$5.16
Price After
$4.96
Q1 FY2026-33.18%
Report Date
Mar 16, 2026
EPS Beat/Miss
+40.7%
Price Before
$6.54
Price After
$4.37
Q4 FY2025-2.22%
Report Date
Nov 6, 2025
EPS Beat/Miss
+3.3%
Price Before
$6.77
Price After
$6.62
Q3 FY2025+0.39%
Report Date
Aug 7, 2025
EPS Beat/Miss
-11.1%
Price Before
$7.73
Price After
$7.76
Q2 FY2025-5.42%
Report Date
Apr 3, 2025
EPS Beat/Miss
-35.7%
Price Before
$7.20
Price After
$6.81
Q1 FY2025-10.36%
Report Date
Jan 2, 2025
EPS Beat/Miss
+7.4%
Price Before
$7.43
Price After
$6.66
Q4 FY2024+14.23%
Report Date
Oct 4, 2024
EPS Beat/Miss
-6.5%
Price Before
$4.71
Price After
$5.38
Avg Beat Reaction-15.25%
Avg Miss Reaction+0.29%
Beat Rate3 / 8 quarters
Largest Move-33.18% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LFCR ends December
Lifecore Biomedical, Inc. (LFCR) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $-0.43 — missing the analyst consensus of $-0.29 by -48.3%. The next LFCR earnings date is expected around September 1, 2026.
Each quarter, investors track LFCR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LFCR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LFCR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LFCR earnings · 5 questionsLifecore Biomedical, Inc.'s next earnings report is expected around September 1, 2026. LFCR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LFCR historically reports after market close (AMC).
LFCR earnings datewhen is LFCR earningsLFCR next earnings datewhen does LFCR report earningsLFCR earnings calendar
▸ Source: FMP · Lifecore Biomedical, Inc. SEC filings · US GAAP · Lifecore Biomedical, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026